Topics

Clinical Trials About "Intrinsic connectomes predictive biomarker remission major depressive disorder" - Page: 3 RSS

00:38 EST 20th February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Intrinsic connectomes predictive biomarker remission major depressive disorder" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Intrinsic connectomes predictive biomarker remission major depressive disorder" on BioPortfolio

We have published hundreds of Intrinsic connectomes predictive biomarker remission major depressive disorder news stories on BioPortfolio along with dozens of Intrinsic connectomes predictive biomarker remission major depressive disorder Clinical Trials and PubMed Articles about Intrinsic connectomes predictive biomarker remission major depressive disorder for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intrinsic connectomes predictive biomarker remission major depressive disorder Companies in our database. You can also find out about relevant Intrinsic connectomes predictive biomarker remission major depressive disorder Drugs and Medications on this site too.

Showing "Intrinsic connectomes predictive biomarker remission major depressive disorder" Clinical Trials 51–75 of 19,000+

Extremely Relevant

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.


Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control. In addition, the tolerability and safety of SR58611A in patients with MDD will be evaluated.

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Long-Term Study of Lu AA21004 in Patients With Major Depressive Disorder

The purpose of the study is to evaluate long-term safety and tolerability of Lu AA21004 over a period of 52 weeks in patients with Major Depressive Disorder having completed 6-week acute treatment.

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder

This study will evaluate emotional processing biases in the brain while viewing facial expressions in adults with current or remitted major depressive disorder and healthy volunteers.

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the SSRI (selective serotonin reuptake inhibitor) escitalopram for major depressive disorder (MDD).

Fish Oil as Adjunct Treatment for Major Depressive Disorder

In this proposed study, the investigators will evaluate the effects of fish oil add-on in treatment of major depressive disorder(MDD).

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

This trial is a 52-week safety study to evaluate the safety of adjunctive Brexpiprazole in outpatients with major depressive disorder.

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)

The investigators are testing a Smartphone-delivered cognitive behavioral therapy (CBT) treatment for major depressive disorder (MDD).

Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder

This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).

A Study of Patients With Major Depressive Disorder and Residual Apathy

The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder and who have residual apathy in the absence of depressed mood.

OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).

Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

This is a validation study that will replicate a completed study designed to assess biomarkers of treatment response to standard antidepressant treatment. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD

Seasonal Affective Disorder (SAD) is a subtype of Major Depressive Disorder, characterized by a recurrent temporal relationship between the season of year, the onset and the remission of a major depressive episode. Estimates of the annual prevalence state that 1-6% of the population will develop SAD with the larger prevalences found at greater extremes in latitude. SAD is most likely triggered by the shortening photoperiod experienced in the winter months leading to a deteriora...

Wellness Monitoring for Major Depressive Disorder

The Wellness Monitoring for Major Depressive Disorder (MDD) study is a prospective, longitudinal, observational study aimed at identifying biomarkers of relapse in MDD. Results may help refine clinical approach to relapse management, and may ultimately help MDD patients sustain wellness while on antidepressant medication.

A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder

The purpose of this study is to describe patient functioning and examine associations between depressive symptoms and measures of the various roles of functioning.

Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder

Among the major depressive disorder (MDD) patients in the follow-up group, 16 were administered with 50 mg of oral sertralin once daily with placebo, whereas 28 were treated with 100 mg of ketoprofen once daily as adjuvant treatment for MDD. Controls do not take any medicine.

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.

Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy

The proposed study is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of antidepressant combination for the treatment of depression. Depressive disorder is one of the most common human diseases with a high burden for every patient, her/his family, health care system and society as a whole. Actual treatment concepts of depressive disorders include pharmacologic, biologic (e.g. electroconvulsive therapy, light therapy) and psychologic the...

Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder

This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an 8-week acute treatment and a 6-month continuation treatment phases. The study will also collect data on the prevalence and pattern of co-morbid anxiety and somatic symptoms and their impact on the recurrence of depression.

Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder

The purpose of this study is to determine safety & efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo & to evaluate quality of sleep, overall quality of life, and effect, if any, on anxiety and satisfaction PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


More From BioPortfolio on "Intrinsic connectomes predictive biomarker remission major depressive disorder"

Quick Search